Generic Name and Formulations:
Ocriplasmin 2.5mg/mL; per vial; soln for intravitreal inj after dilution; contains mannitol; preservative- and latex-free.
Indications for JETREA:
Treatment of symptomatic vitreomacular adhesion.
Give by intravitreal inj. 0.125mg (0.1mL of the diluted soln) once as a single dose to the affected eye.
For ophthalmic intravitreal inj only. Monitor for elevation in intraocular pressure immediately after inj. Monitor for decreased vision. Repeated administration in the same eye: not recommended. Treatment in the other eye is not recommended within 7 days of the initial inj. Pregnancy (Cat.C). Nursing mothers.
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema; intraocular inflammation/infection/hemorrhage, increased intraocular pressure, yellowish vision.
Single-use vial (0.2mL)—1
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age